In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Madrigal reverse merges with Synta; newco to focus on cardio-metabolic diseases

Executive Summary

Synta Pharmaceuticals Corp., a public oncology company, reverse merged with private cardio-metabolic firm Madrigal Pharmaceuticals Inc. Synta issued 253.9mm shares to Madrigal, valuing the transaction at $61mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Reverse Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Full Acquisition

Related Companies